«

»

FDA, facing intense criticism, narrows use of controversial Alzheimer’s drug to patients with early-stage disease

The revised label clarifies that the drug, called Aduhelm, is intended for patients with early-stage disease — the population that participated in clinical trials of the drug.

Read the full post at Health
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive